Lactate dehydrogenase A inhibition prevents RANKL-induced osteoclastogenesis by reducing enhanced glycolysis
Journal of Pharmacological Sciences · 2023-12 · 153 (4) · 197-207
DOI: 10.1016/j.jphs.2023.09.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2023-12. Verfasst von Tsuyoshi Nishioku und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, …. Hauptthemen laut MEDLINE: Osteogenesis, Bone Resorption. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osteoclasts are multinucleated, specializes bone-resorbing cells that are derived from the monocyte/macrophage lineage. Excessive resorbing activities of osteoclasts are involved in destructive bone diseases. The detailed mechanism of acidification at the bone adhesion surface during the bone resorption process of osteoclasts remains to be defined. During glycolysis, pyruvate proceeds to the tricarboxylic cycle under aerobic conditions and pyruvate is converted to lactate via lactate dehydrogenase A (LDHA) under anaerobic conditions. However, tumor cells produce ATP during aerobic glycolysis and large amounts of pyruvate are converted to lactate and H+ by LDHA. Lactate and H+ are excreted outside the cell, whereby they are involved in invasion of tumor cells due to the pH drop around the cell. In this study, we focused on aerobic glycolysis and investigated the production of lactate by LDHA in osteoclasts. Expression of LDHA and monocarboxylate transporter 4 (MCT4) was upregulated during osteoclast differentiation. Intracellular and extracellular lactate levels increased with upregulation of LDHA and MCT4, respectively. FX11 (an LDHA inhibitor) inhibited osteoclast differentiation and suppressed the bone-resorbing activity of osteoclasts. We propose that inhibition of LDHA may represent a novel therapeutic strategy for controlling excessive bone resorption in osteoporosis and rheumatoid arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, Japan. Electronic address: nishiokut@niu.ac.jp.
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, Japan.
Zitieren
APA
Nishioku, T., Anzai, R., Hiramatsu, S., Terazono, A., Nakao, M., & Moriyama, M. (2023). Lactate dehydrogenase A inhibition prevents RANKL-induced osteoclastogenesis by reducing enhanced glycolysis. Journal of Pharmacological Sciences, 153(4), 197-207. https://doi.org/10.1016/j.jphs.2023.09.005
Vancouver
Nishioku T, Anzai R, Hiramatsu S, Terazono A, Nakao M, Moriyama M. Lactate dehydrogenase A inhibition prevents RANKL-induced osteoclastogenesis by reducing enhanced glycolysis. Journal of Pharmacological Sciences. 2023;153(4):197-207. doi:10.1016/j.jphs.2023.09.005
BibTeX
@article{Nishioku2023,
author = {Nishioku, Tsuyoshi and Anzai, Rumi and Hiramatsu, Sami and Terazono, Ayaka and Nakao, Mamiko and Moriyama, Miyu},
title = {Lactate dehydrogenase A inhibition prevents RANKL-induced osteoclastogenesis by reducing enhanced glycolysis},
journal = {Journal of Pharmacological Sciences},
year = {2023},
volume = {153},
number = {4},
pages = {197--207},
doi = {10.1016/j.jphs.2023.09.005}
}
EUVIMED